Pharma Capital

Abzena's John Burt 'very pleased' to close Taiwanese biopharma Thiobridge deal

John Burt, chief executive of Abzena plc (LON:ABZA) tells Proactive they've inked an agreement with a Taiwanese biopharmaceutical company worth up to £128mln to license out its ThioBridge technology.

ThioBridge is an antibody drug conjugate (ADC) linker, which in layman’s terms means it attaches antibodies and other proteins to drugs.

 

View full ABZA profile

Abzena plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.